Robert J. Walden,
Managing Partner
“As former President and Chief Operating Officer for both MedImmune and Human Genome Sciences, Mel Booth has played a key role toward shaping the life science industry in Maryland. Now as Chairman of Edge BioRealty, I anticipate that Mel will continue this track record in serving the real estate needs of the life science community. Mel serves his clients with innovative real estate solutions drawn from 34 years of executive level life science experience.”
- David W. Edgerley, Secretary of Maryland Department of Businessand Economic Development
Combining Life Science And Real Estate Expertise
The EDGE BioRealty team offers its clients an unprecedented combination of executive-level real estate and life science experience to deliver real estate solutions tailored to the unique, mission-critical facility needs of the life science industry.
Using Our Experience For Your Success
Our life science executives have more than 60 years experience managing some of the area’s largest life science companies and guiding them through the design, approval, financing and development of their corporate headquarters. These individuals understand how real estate needs – and financing alternatives – can vary significantly for different types of companies within the life science industry (e.g. therapeutic, diagnostic, contract research, etc.) and/or their stage of development (e.g. pre-clinical, clinical, commercial). This first-hand knowledge gives us the unique ability to more effectively understand and evaluate our client’s real estate needs – not just from an operational standpoint, but from a strategic and financial perspective as well.
Our team of proven real estate professionals, in combination with our life science specialists, provides our clients with more than 150 years of collective experience in successfully delivering mission-critical real estate solutions. Our real estate principals have completed some of the largest life science real estate transactions in the mid-Atlantic region and, overall, have successfully concluded over $6 billion in diverse commercial and life science real estate transactions. Representative transactions conducted by our life science and real estate professionals include:
$1.385B real estate monetization for Human Genome Sciences, Inc. – GWCAR’s “Sales & Finance Transaction of the Year – MD”
National site selection / incentive negotiation for MedImmune, Inc. world headquarters – Washington Business Journal’s “Best Office Lease – Suburban”
National site selection / incentive negotiation for the American Type Culture Collection 106,000 sq. ft. corporate headquarters and research facility
$92.5M real estate disposition for Human Genome Sciences, Inc. – Washington Business Journal’s “Sale Transaction of the Year”
53,000 sq. ft. financing / lease / build out of Large Scale Biology Corporation’s corporate research facility
Site selection / incentive negotiation for Human Genome Sciences, Inc. 127,000 sq. ft. pilot plant – Washington Business Journal’s “Best Industrial Transaction of the Year”
30,000 sq. ft. financing / build out and relocation of Osiris Therapeutic, Inc. corporate research facility
$8.5M disposition of a 58,000 sq. ft. biopharmaceutical manufacturing facility
Together, our extensive life science expertise and proven commercial real estate capabilities will provide our clients with a knowledgeable assessment of their needs and the successful execution of an effective solution.
For more information about our Life Science consulting services, contact Bob Walden at 301-222-0207 or bwalden@edgebiorealty.com.